SAVED
File name .JPG
File alt. text
Image should be px wide x px tall.
Select Image
home - Colon - Various Colitides - Diversion Colitis Written by Dr Sebastian Zeki

Diversion Colitis

Carbs SCFA’s (butyrate, acetate, propionate) Anaerobic bacterial metabolism Carbohydrates absorbed by ion exchange and diffusion and oxidised by colonocyte Normal Carbs SCFA’s (butyrate, acetate, propionate) Anaerobic bacterial metabolism Diverted colon Histological evidence of diversion colitis = 95%Symptomatic patients =10% Role of Carbohydrate in the Colon They supply 70% of the fuel used by mucosal cells.They modulate fluid and electrolyte transport.They regulate colonic motility.They regulate mucosal blood flow. Histological FeatureDistinction from IBD is difficult.Diffuse cellular infiltrate and prominent lymphoid follicular hyperplasia may suggest diversion colitis. Rectal bleeding, tenesmus, mucus discharge, and abdominal pain Begin within a few months after surgery or after a long delay. Treatments:Reanastomosis.Short chain fatty acid enemas.5 ASA. Diversion colitis Definition— Diversion colitis is an inflammatory process that occurs in segments of the colorectum that are diverted from the fecal stream by surgery. The enema solution consists of sodium acetate (60 mmol), sodium propionate (30 mmol) and sodium n-butyrate (40 mmol) with additional sodium chloride (22 mmol) to yield an osmolality of 280 to 290 mosmol/L which is similar to plasma. The pH is adjusted to 7.0 with sodium hydroxide. -bd for 6 weeks Written by Dr Sebastian Zeki

Related Stories

•Differential Expression of IFI16, IL-33 and CD55 Link Potential Common Pathogenic Mechanisms for COVID-19 and Ulcerative Colitis

•Identifying Genetic Factors Influencing the Development of Anti-Drug Antibodies in Inflammatory Bowel Disease: A Scoping Review

•Rituximab-Induced Esophageal Ulcers and Strictures Presenting as Dysphagia

•LncRNA-Associated ceRNA Network in the Spinal Cord Reveals the Central Mechanism of Chronic Inflammatory Visceral Pain

•Immunoregulatory protein-hybrid extracellular vesicles via self-loadable backbone cyclization for oral inflammatory bowel disease therapy